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ABSTRACT Atopic dermatitis (AD) is a common chronic and relaps-
ing, non-contagious inflammatory skin disorder, characterized by 
skin barrier impairment and baseline immune irregularities. The 
literature on the relationship between AD and cutaneous delayed-
type hypersensitivity is inconclusive. There is an ongoing debate 
whether contact sensibility (CS) is found more or less often among 
patients with AD. Aim of the study was to evaluate the incidence of 
contact sensitivity (positive patch test reactions) in patients with and 
without AD. We patch tested a total of 2143 patients (563 men and 
1580 women). There were 226 patients with history of AD; 61 (27%) 
men and 165 (73%) women. The patient group without AD consisted 
of 1917 patients, 502 (26%) male and 1415 (74%) female patients, 
who were referred to our Department with clinical suspicion of al-
lergic contact dermatitis (ACD). A patch test was performed with 
the baseline series, and readings were performed on days D2, D3, 
and D7. Among patients with AD, 109 (48.2%) had a positive patch 
test reaction to at least one allergen, whereas 1094 (57.1%) patients 
with no history of AD had a positive patch test reaction. The most 
common positive allergens in patients with AD were nickel (II) sulfate 
(13.3%), thimerosal (12.4%), cobalt (II) chloride (11.5%), methylisothi-
azolinone (MI) (8.4%), fragrance mix I (6.6%), potassium dichromate 
(5.3%), methyldibromo glutaronitrile (4.0%), and carba mix (4.0%). 
The results of our study agree with previous findings that there is 
no significant difference in prevalence of CS between the atopic and 
nonatopic populations. 
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INTRODUCTION
Atopic dermatitis (AD) is a common chronic and 
relapsing, non-contagious inflammatory skin disor-
der characterized by typical morphology/distribution 
of dermatitis, pruritus, and xerosis (1). Contact derma-
titis (CD) is an inflammatory skin reaction caused by 
direct contact with noxious agents in the environ-
ment and typically develops following repeated or 
prolonged topical exposure to chemical allergens 
(2,3). Contact sensitivity (CS) is the term used to de-
scribe a positive patch test reaction and is character-
ized by induction of a specific T-lymphocyte response 
(3,4). To diagnose allergic contact dermatitis (ACD) in 
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a patient, the patient must have a contact sensitivity 
and clinical picture of dermatitis with clinically rel-
evant exposure to the contact allergen (5). Induction 
of CS and elicitation of ACD depend on the sensitizing 
potential of the hapten, dose per unit area, presence 
of the irritants, race, gender, age, and genetic predis-
position (6). The incidence of AD varies between 11% 
and 21% in Northern Europe (5), while CS affects up to 
20% of the general population (7). Both diseases have 
a marked impact on quality of life (8,9). Experimental 
studies have clearly shown that individuals with AD 
have suppressed CS due to their disease (10). General 
population and clinical studies have found diverging 
outcomes, some suggesting a positive association 
between AD and CS (4,11-17). Clinical studies have 
shown that exposure to contact allergens used in 
topical products may result in CS, but sensitization 
trials have shown that especially moderate to severe 
AD is inversely associated with CS (18-20). 
OBJECTIVES
To evaluate the incidence of CS (positive patch 
test reactions) in patients with and without AD.
PATIENTS AND METHODS
We patch tested a total of 2143 patients, 563 men 
and 1580 women, between March 2, 2015 and Febru-
ary 27, 2017. There were 226 patients with history of 
AD and 1917 patients without AD, who were referred 
to our Department with clinical suspicion of allergic 
contact dermatitis (ACD). Atopic dermatitis was diag-
nosed clinically, using Hanifin and Rajka criteria (21). 
We patch tested patients with AD when we suspect-
ed ACD (persistent and therapy refraction dermatitis 
especially on the face and hands and worsening of 
the dermatitis after application of local therapy). The 
patch test was performed with the baseline series 
(Imunološki zavod, Zagreb, Croatia; Chemotechnique, 
Vellinge, Sweden) using Finn Chambers on Scanapor 
tape, applied to the upper back area, and readings 
were performed on day (D) D2, D3, and D7.
RESULTS
We patch tested 2143 patients: 563 men and 
1580 women. Of the 2143 patients tested, 226 had 
AD. There were 61 (27%) men and 165 (73%) women 
with AD and 502 (26%) male and 1415 (74%) female 
patients without AD. Among patients with AD, 109 
(48.2%) had a positive patch test reaction to at least 
one allergen, whereas 1094 (57.1%) patients with no 
history of AD had a positive patch test reaction (Fig-
ure 1). A total of 87 (52.7%) women and 22 (36.1%) 
men with AD had a positive patch test reaction to at 
least one allergen, while 837 (59.2%) women and 257 
(51.2%) men without AD had a positive patch test 
reaction. The median age of patients with AD was 
24.6 years and 44.4 years in patients without AD. The 
most common positive allergens in patients with AD 
were nickel (II) sulfate (13.3%), thimerosal (12.4%), co-
balt (II) chloride (11.5%), methylisothiazolinone (MI) 
(8.4%), fragrance mix I (6.6%), potassium dichromate 
(5.3%), methyldibromo glutaronitrile (4.9%), and car-
ba mix (4.0%) (Figure 2, Table 1). In patients without 
AD, the most common positive allergens in the patch 
test were nickel (II) sulfate (21.4%), cobalt (II) chloride 
(14.0%), MI (12.9%), thimerosal (12.2%), potassium di-
chromate (6.6%), MCI/MI (6.3%), fragrance mix (6.2%), 
methyldibromo glutaronitrile (5.8%), and myroxylon 
pereirae (4.4%) (Figure 3, Table 1). A higher number 
of patients with AD had a positive patch test reac-
tion to carba mix and to lanolin alcohol compared 
with patients without AD (Table 1). A lower number 
of patients with AD had a positive patch test reaction 
to potassium dichromate, cobalt (II) chloride hexa-
hydrate, nickel (II) sulfate hexahydrate, myroxylon 
pereirae, neomycin sulfate, MCI/MI, and MI than pa-
tients without AD (Table 1). There were no differences 
between patients with and without AD for fragrance 
mix I, formaldehyde, thimerosal, tixocortol-21-piva-
late, and budesonide (Table 1). 
DISCUSSION
There is ongoing debate in the literature regard-
ing the relationship between AD and contact derma-
titis. Several studies reported reduced CS (4,12,13), 
others found a positive relationship (4,11,14-17), 
while some studies found atopy and contact derma-
titis to be independent (18). We found more positive 
patch test reactions in patients without AD (57.1%) 
compared with patients with AD (48.2%). The results 
of our study agree with previous findings that there is 
no significant difference in prevalence of CS between 
the atopic and non-atopic population (4,14,23). In a 
recent general population study that included 6161 
patients, average prevalence of CS in patients with 
AD was 29.6%, while being 22.5% in those without 
AD (4). In the same study in a referred population 
group (n=50,544), the average prevalence of CS in 
patients with AD was 49.9%, which is the same as in 
our study (48.2%), and 54.9% in patients without AD 
(4). Results of a meta-analysis showed that patients 
with and without AD have similar prevalence of CS, 
with an inverse association in patients referred for 
patch testing (4). In studies on the general popula-
tion, higher CS rates were found in individuals with 
AD (4). The higher proportion of positive patch test 
reactions in patients without AD could be explained 
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   Table 1.  Positive patch test results in patients with atopic dermatitis and patients without atopic  dermatitis
Allergen in baseline series Patients with AD
(N=226)
Patients without AD 
(N=1917)
p-value
1 Potassium dichromate 12 (5.3%) 127 (6.6%) 0.538
2 Cobalt(II) chloride hexahydrate 26 (11.5%) 269 (14.0%) 0.347
3 Nickel (II) sulfate hexahydrate 30 (13.3%) 410 (21.4%) 0.006
4 Fragrance mix I 15 (6.6%) 118 (6.2%) 0.89
5 Epoxy resin 0 (0.0%) 17 (0.9%) 0.245
6 p-phenylenediamine (PPD) 2 (0.9%) 29 (1.5%) 0.65
7 Myroxylon pereirae 2 (0.9%) 84 (4.4%) 0.007
8 N-Isopropyl-N-phenyl-4-phenylenediamine (IPPD) 0 (0.0%) 15 (0.8%) 0.392
9 Mercapto mix 4 (1.8%) 15 (0.8%) 0.132
10 Thiuram mix 3 (1.3%) 55 (2.9%) 0.274
11 Carba mix 9 (4.0%) 46 (2.4%) 0.23
12 Paraben mix 0 (0.0%) 7 (0.4%) 1
13 Coal tar 2 (0.9%) 70 (3.7%) 0.02
14 Neomycin sulfate 3 (1.3%) 79 (4.1%) 0.041
15 Benzocaine 1 (0.4%) 15 (0.8%) 0.484
16 Colophonium 1 (0.4%) 35 (1.8%) 0.17
17 Formaldehyde 3 (1.3%) 27 (1.4%) 1
18 Thimerosal 28 (12.4%) 234 (12.2%) 0.915
19 Phenyl mercuric acetate 2 (0.9%) 23 (1.2%) 1
20 Sesquiterpene lactone mix 4 (1.8%) 23 (1.2%) 0.521
21 Clioquinol 0 (0.0%) 6 (0.3%) 1
22 Quaternium -15 0 (0.0%) 10 (0.5%) 0.612
23 2-Methoxy-6-n-pentyl-4-benzoquinone 0 (0.0%) 7 (0.4%) 1
24 Budesonide 4 (1.8%) 36 (1.9%) 1
25 Tixocortol-21-pivalate 1 (0.4%) 8 (0.4%) 1
26 Methylisothiazolinone + methylchloroisothiazolinone 5 (2.2%) 121 (6.3%) 0.01
27 Fragrance mix II 3 (1.3%) 53 (2.8%) 0.27
28 Methylisothiazolinone 19 (8.4%) 247 (12.9%) 0.068
29 Methyldibromo glutaronitrile 11 (4.9%) 112 (5.8%) 0.656
30 Lanolin alcohol 8 (3.5%) 16 (0.8%) 0.001
by patients selection bias, since only patients with 
suspected CD are patch tested, and not the general 
population, while patients with AD were mostly re-
ferred to patch test just to rule out CS, therefore CS is 
less expected (4,13).
It is unclear whether patients with AD have an 
increased risk for CS or if they are at higher risk to 
become sensitized due to increased exposure to 
chemicals in topical products applied to the skin on 
a daily basis along with impaired skin barrier function 
(4,11,19). However, the immune profile and suppres-
sion of cell-mediated immunity suggest lower risk 
(4,11). It is possible that AD not only results in CS but 
also that CS may result in AD in select individuals, or 
at least worsen the course of the disease (10,24). The 
risk to develop AD is increased in individuals with 
primary skin barrier impairment and primary im-
mune dysregulation, and filaggrin gene mutations 
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(FLG mut) have the highest impact on impairment 
of barrier function (4,10,25,26). There is evidence of 
an almost 2-fold increase in absorption of irritants, 
chemicals, and contact allergens in the skin of pa-
tients with AD (27). 
Patients with AD were much younger than patients 
without AD, which is a finding consistent with the re-
sults from previous studies (14,17,28). Contact allergy 
to the majority of allergens is strongly age dependent 
(10,15,17,18,27,29-31). The differences in the age are 
due to the differences in the exposure, frequency, 
type, and length of exposure required to induce sen-
sitization to specific chemicals (14). AD predisposes a 
higher risk of ACD in children compared with adults 
(31). Risk factors for positive patch test reactions in 
a recent study were onset of dermatitis before 6 
months of age and IgE-mediated sensitization, indi-
cating that those that have been the most strongly 
exposed will have the higher incidence of CS (3,19). 
A higher frequency of positive patch test reactions 
and multiple sensitizations were found in patients 
with severe AD (16,23,32). Prevalence was higher in 
patients with AD who had FLG loss of function mu-
tation, when compared with individuals without AD 
and wild-type FLG, suggesting a severity of disease 
may increase a risk of CS (7,10,16,28,32). A general 
population study showed that patients with AD, es-
pecially those with FLG mut, had a higher prevalence 
of CS in topical products (3,6,18).
Although many studies have found chromium to 
be more statistically frequently positive in patients 
with AD (4,33) (which could be explained by a falsely 
positive patch test reaction due to the irritative po-
tential of chromium) (3,7), our results showed lower 
positive reactions in patients with AD (5.3%) when 
compared with the group of patients without AD 
(6.6%), and this was similar to observations reported 
in other studies (23). 
Previous epidemiological studies suggested an 
increased prevalence of nickel sensitization and ACD 
(14), although results of meta-analysis did not find a 
positive correlation (4). We found lower positive patch 
test reactions to nickel (II) sulfate in patients with AD, 
which is consistent with other reports (16). Ear-pierc-
ing is still considered to be the most important step 
in nickel-sensitization and it is speculated that nickel 
sensitivity is expected to be less dependent on skin 
barrier function impairment because barrier integrity 
is often violated by ear-piercing (25). A slight associa-
tion of loss-of function FLG mut and CS to nickel has 
been found, with a strong association when analysis 
is restricted to female patients (25). 
Our results showed that patients with AD were 
more likely to have a positive reaction to carba mix 
and to lanolin alcohol than patients without AD, 
Figure 1. Contact sensitivity in patients with and without 
atopic dermatitis.
Figure 2. Positive patch test results in patients with atopic dermatitis.
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which could be explained by frequent usage of these 
substances in the emollients that they were using. 
More patients with AD, compared with patients 
without AD, had fragrance CS, which is in correlation 
with results of other studies (6,10). However, there 
were some reports in which fewer patients with AD 
than patients without AD had fragrance allergy (23).
Many cosmetics and topical medications and hy-
giene products, including liquid soaps, shampoos, 
and conditioners, have a high water content and re-
quire chemical preservation (16). Parabens, formal-
dehyde, and formaldehyde releasers are commonly 
used as preservatives (16). Formaldehyde is a strong 
sensitizer, irritant, and potential carcinogen, and has 
therefore been mostly replaced by formaldehyde re-
leasers (16). However, it is still used is some hair care 
and nail care products today (34). In our study, only 
3 (1.3%) patients with AD were positive to formalde-
hyde, while formaldehyde releaser (quaternium-15) 
and parabens were negative, which is not in correla-
tion with other reports (16) that demonstrated sig-
nificantly higher allergic responses to formaldehyde 
releasers in patients with AD. 
Contact allergy to biocides is still common 
throughout Europe. MI prevalence is 4.5%, and MCI/
MI mixture prevalence is 4.1% (35). In our study, there 
was a relatively high percentage of both MI and MCI/
MI (Table 1) in both studied groups, which can be ex-
plain as the result of using leave-on and rinse-off skin 
and hair care products containing those substances. 
There were 19 (8.4%) patients with AD positive to 
MI. Our study ended on February 27, 2017, and as of 
January 2017 MCI/MI and MI have been forbidden in 
leave-on cosmetics (36). 
Methyldibromo glutaronitrile (MDBGN) was an 
allergen commonly used in cosmetics and personal 
care products, such as body lotions, facial lotions, 
hand lotions, sunscreen lotions, baby lotions, shower 
gels, shampoos, and massage oils (30,37). Since 2005, 
the European Union banned the use of MDBGN in 
stay-on products and then later in 2007 also in rinse-
off products (30,37). We found a positive reaction to 
MDBGN in 4.9% patients with AD and in 5.8% patients 
without AD.
Coal tar is substance that can reduce inflamma-
tion, itching, and scaling and is mostly used in treat-
ment of psoriasis, seborrheic dermatitis, and eczema 
(38). In our study, slightly higher positive reactions 
were found in patients without AD.
When the eczematous lesions do not respond 
properly to corticosteroid treatment or even worsen 
when topical corticosteroids are applied, patch test-
ing with corticosteroid markers (tixocortol pivalate, 
budesonide, and hydrocortisone-17-butyrate) should 
be performed (39). Corticosteroids are not potent al-
lergens, but CS to them is not that infrequent, since 
patients with AD are treated with corticosteroids 
since early childhood (39). More positive reactions can 
be expected on later patch test readings (day 7) (13). 
Although both of our tested groups were previously 
treated with corticosteroids, CS to corticosteroids was 
not a frequently positive allergen among our patients. 
We found positivity to tixocortol-21-pivalate in 0.4% 
of patients in both studied groups, and 1.8% positiv-
ity to budesonide in patients with AD compared with 
1.9% positivity in patients without AD.
Thimerosal is used as an ophthalmic preserva-
tive, a topical anti-infective, and a topical veterinary 
Figure 3. Positive patch test reactions in patients without atopic dermatitis.
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antibacterial and antifungal agent. It could be found 
in vaccines, antitoxins, skin testing allergens, antisep-
tics, contact lens solutions, and cosmetic products 
like eye make-up (40). A positive reaction to thimero-
sal was irrelevant to contact allergy in our patients. It 
may indicate exposure to vaccines during childhood.
While many studies reported significantly higher 
positive reactions to sesquiterpene lactone mix (4,6), 
which can cause worsening of AD during spring and 
summer months due to airborne dermatitis, in our 
study there was no difference between the two stud-
ied groups (1.8% of the patients with AD and 1.2% of 
the patients without AD had a positive reaction).
CONCLUSIONS
CS in patients with AD should be always consid-
ered in cases of therapy-resistant AD and in cases of 
worsening of skin condition after application of local 
therapy. Patients with AD with suspected CS require 
careful evaluation of clinical and personal history, 
known allergies, hobbies and leisure activities, infor-
mation on topical medication usage, and use of or 
exposure to cosmetics and skin care products. 
LIMITATIONS OF THE STUDY
Only patients with AD suspected of having ACD 
were patch tested, not the general population, while 
patients without AD were mostly referred to patch 
test just to rule out CS. We have data for contact al-
lergy for all patch-tested patients, while data on rele-
vance is missing. Another study limitation is the large 
differences between age groups. We did not evaluate 
the severity of the AD, which is expected to be an 
important risk factor in development of CS, and we 
do not have data on FLG mut in the group of patients 
with AD. 
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